COMBINATION OF MT1 AND MT2 MELATONIN RECEPTOR AGONISTS AND A NOREPINEPHRINE/DOPAMINE REUPTAKE INHIBITOR

摘要

The present invention relates to the use of a combination of a MTl and MT2 melatonin receptor agonists and a norepinephrine/dopamine reuptake inhibitor (NDRI) for the treatment of depression and other affective disorders. It specifically relates to the use of a combination of agomelatine and bupropion for the treatment of depression and other affective disorders.